Guilt by association: A historical perspective on huggins, testosterone therapy, and prostate cancer

Journal of Sexual Medicine

Volumn 5, Issue 8, 2008, Pages 1834-1840

  Morgentaler, Abraham ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Prostate Cancer; Risks; Testosterone

Indexed keywords

ESTROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

CANCER GROWTH; CANCER RELAPSE; CANCER RISK; CASTRATION; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; HYPOGONADISM; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

EID: 48749083358     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.00889.x     Document Type: Review

References (30)

1. Gooren LJ, Behre HM, Saad F, Frank A, Schwerdt S. Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. Aging Male 2007; 10: 173-81.
2. Morgentaler A. Testosterone and prostate cancer: An historical perspective on a modern myth. Eur Urol 2006; 50: 935-9.
3. Endogenous Hormones, Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. JNCI 2008; 100: 170-83.
4. Carpenter WR, Robinson W, Godley PA. Getting over testosterone: Postulating a fresh start for etiologic studies of prostate cancer. JNCI 2008; 100: 158-9.
5. Morgentaler A, Bruning CO III, DeWolf WC. Incidence of occult prostate cancer among men with low total or free serum testosterone. JAMA 1996; 276: 1904-6.
6. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482-92.
7. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
8. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-23.
9. Prout GR, Brewer WR. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 1967; 20: 1871-8.
10. Fowler JE, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126: 372-5.
11. Walsh PC, Donker PJ. Impotence following radical prostatectomy: Insight into etiology and prevention. J Urol 1982; 128: 492-7.
12. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16.
13. Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001; 58 (2A suppl): 5-9.
14. Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990; 144: 1479-80.
15. Labrie F, Dupont A, Belanger A, Lefebvre FA, Cusan L, Monfette G, Laberge JG, Emond JP, Raynaud JP, Husson JM, Fazekas AT. New hormonal treatment in cancer of the prostate: Combined administration of an LHRH agonist and an antiandrogen. J Steroid Biochem 1983; 19: 999-1007.
16. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24.
17. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010.
18. Hsing AW. Hormones and prostate cancer: What's next? Epidemiol Rev 2001; 23: 42-58.
19. Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007; 34: 555-63.
20. Huggins C. Endocrine-induced regression of cancers. Cancer Res 1967; 27: 1925-30.
21. Turner ME, Pratkanis AR. Twenty-five years of groupthink theory and research: Lessons from the evaluation of a theory. Organ Behav Hum Decis Process 1998; 73: 105-15.
22. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R, etal. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (Buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (Nilutamide). N Engl J Med 1989; 321: 413-8.
23. Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB. The gonadotropin-releasing hormone antagonist Abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001; 165: 1585-9.
24. Morgentaler A. Cultural biases and scientific squabbles: The challenges to acceptance of testosterone therapy as a mainstream medical treatment. Aging Male 2007; 10: 1-2.
25. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004; 172: 920-2.
26. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533-6.
27. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007; 109: 536-41.
28. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 2004; 64: 8867-75.
29. Bonaccorsi L, Muratori M, Marchiani S, Forti G, Baldi E. The androgen receptor and prostate cancer invasion. Mol Cell Endocrinol 2006; 246: 157-62.
30. Morgentaler A. Testosterone deficiency and prostate cancer: Emerging recognition of an important and troubling relationship. Eur Urol 2007; 52: 623-5.